StarT
  • StarT project
  • ESR PROFILES
  • Partners
  • papers
  • News
  • Agenda
  • Contact

ESR9: Antisense oligonucleotide-based splice modulation for deep-intronic mutations in ABCA4

Picture
Partner
Radboud University Medical Center Nijmegen, The Netherlands (www.ru.nl/donders/research/theme-2-perception-action-control/research-groups-theme-2/genetic-therapy-inherited-retinal-disease/)
Supervisor
Dr. R. Collin
Nuria Suárez Herrera
I obtained my BSc in Biochemistry and MSc in Translational Medicine at Universitat de Barcelona. At that time, I did an internship for almost two years in Dr. Hernández-Gea’s lab (Hepatic Hemodynamics and Portal Hypertension, IDIBAPS), where I conducted translational research in liver fibrosis, aiming to develop therapies to prevent fibrosis progression. Afterwards, driven by my interest in bench-to-bedside research, I joined Dr. Collin’s group (Human Genetics Department, Radboudumc) as a PhD student in StarT Project, where I am currently working on the development of novel antisense oligonucleotide-based splice modulation therapies for deep-intronic ABCA4 mutations in Stargardt Disease.
Abstract
Antisense oligonucleotides (AONs) are molecules that are able to modulate pre-mRNA splicing of target genes, either by blocking or by recruiting factors that are essential for splicing. P1-UGent, P2-RUMC and others have identified several deep-intronic ABCA4 variants that result in the insertion of pseudexons into ABCA4 mRNA (e.g. c.4539+1100A>G; c.4539+1106C>T; c.4539+2001G>A and c.4539+2028C>T). In this project, ESR9 will employ AONs to redirect ABCA4 splicing in order to produce wild-type ABCA4 transcripts, employing patient-derived fibroblasts or minigene splicing assays. Following the identification of the most potent AON molecules for each mutation iPSC-derived PPCs from patients with the corresponding mutations will be generated. Subsequently, AONs will be administered to these PPCs, to further optimise the efficacy of the AONs in a relevant cell model. ESR9 will employ transcriptomics  to study potential off-target effects of AON administration. These data will shed light on the pre-clinical efficacy and safety of AON-based splice correction therapy for ABCA4-associated IRD, and allow to identify new targets for initiating clinical studies in humans.
StarT
ERS profiles
Partners
Jobs
News
Agenda
Contact

This project has received funding from the European Union's Horizon 2020 research and innovation programme Marie Sklodowska-Curie Innovative Training Networks (ITN) under grant No.
813490
Picture
  • StarT project
  • ESR PROFILES
  • Partners
  • papers
  • News
  • Agenda
  • Contact